Loss of CD22 expression and expansion of a CD22
Adult
Aged, 80 and over
Allografts
Antibodies, Bispecific
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
B-Lymphocytes
/ chemistry
Clone Cells
Female
Flow Cytometry
Hematopoietic Stem Cell Transplantation
Humans
Imatinib Mesylate
/ administration & dosage
Immunophenotyping
Inotuzumab Ozogamicin
/ therapeutic use
Lymphocyte Subsets
/ chemistry
Male
Middle Aged
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ blood
Recurrence
Salvage Therapy
Sialic Acid Binding Ig-like Lectin 2
/ analysis
Sorafenib
/ therapeutic use
Treatment Failure
Young Adult
B-ALL
CD22
Immunotherapy
Inotuzumab-Ozogamicin
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
10
04
2021
accepted:
04
07
2021
pubmed:
1
8
2021
medline:
26
10
2021
entrez:
31
7
2021
Statut:
ppublish
Résumé
Treatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody-drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. Flow cytometry is essential to assess antigen-expression prior to treatment initiation of antigen-directed immunotherapies. Here, we present flow cytometric and clinical data of three adult patients with r/r B-ALL who failed treatment with InO associated with reduced or lost antigen-expression. In addition, we present comparative data on two different diagnostic CD22-specific antibody clones that exhibit significant differences in staining intensities.
Identifiants
pubmed: 34331563
doi: 10.1007/s00277-021-04601-0
pii: 10.1007/s00277-021-04601-0
pmc: PMC8510963
doi:
Substances chimiques
Antibodies, Bispecific
0
Antineoplastic Agents, Immunological
0
CD22 protein, human
0
Sialic Acid Binding Ig-like Lectin 2
0
blinatumomab
4FR53SIF3A
Imatinib Mesylate
8A1O1M485B
Sorafenib
9ZOQ3TZI87
Inotuzumab Ozogamicin
P93RUU11P7
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2727-2732Informations de copyright
© 2021. The Author(s).
Références
Hm K, Dj D, Stelljes M, Liedtke M, Stock W, Gökbuget N, O’brien Sm, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani As, (2019) Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 Ino-Vate study. Cancer 125(14):2474–2487. https://doi.org/10.1002/Cncr.32116
Stelljes M, Raffel S, Wäsch R, Scholl S, Kondakci M, Rank A, Haenel M, Martin S, Schwab K, Knaden J, Wethmar K, Sauer T, We B, Lenz G, Dugas M, Brüggemann M, Goekbuget N, Alakel N (2020) First results of an open label phase II study to evaluate the efficacy and safety of inotuzumab ozogamicin for induction therapy followed by a conventional chemotherapy based consolidation and maintenance therapy in patients aged 56 years and older with acute lymphoblastic leukemia (Initial-1 trial). Blood 136(Supplement 1):12–13. https://doi.org/10.1182/Blood-2020-136920
doi: 10.1182/Blood-2020-136920
Kantarjian Hm SuY, Ej J, Bhattacharyya H, Yan E, Jc C, Di M (2018) Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer 124(10):2151–2160. https://doi.org/10.1002/Cncr.31317
doi: 10.1002/Cncr.31317
pubmed: 29508899
Raponi S, Stefania De Propris M, Intoppa S, Laura Milani M, Vitale A, Elia L, Perbellini O, Pizzolo G, Foá R, Guarini A (2011) Flow cytometric study of potential target antigens (Cd19, Cd20, Cd22, Cd33) for antibody-based immunotherapy in acute lymphoblastic leukemia. Analysis of 552 cases. Leuk Lymphoma 52(6):1098–1107. https://doi.org/10.3109/10428194.2011.559668
doi: 10.3109/10428194.2011.559668
pubmed: 21348573
Hoelzer D, Gökbuget N (2012) Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 26(1):25–32. https://doi.org/10.1016/J.Blre.2011.08.001
doi: 10.1016/J.Blre.2011.08.001
pubmed: 21958552
Mn D, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, Rosenthal E, Bourquin J-P, Sartor M, Schumich A, Karawajew L, Mejstrikova E, Maglia O, Mann G, Ludwig W-D, Biondi A, Schrappe M, Basso G (2018) Aieop-Bfm consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom 94(1):82–93. https://doi.org/10.1002/Cyto.B.21518
doi: 10.1002/Cyto.B.21518
Lanza F, Maffini E, Rondoni M, Massari E, Ac Faini, Malavasi F (2020) Cd22 expression in B-cell acute lymphoblastic leukemia. Biological significance and implications for inotuzumab therapy in adults. Cancers 12(2):303. https://doi.org/10.3390/Cancers12020303
doi: 10.3390/Cancers12020303
pmcid: 7072635
Lanza F, Maffini E, Saraceni F, Massari E, Rondoni M, Daghia G, Olivieri A, Cerchione C, Martinelli G (2020) New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. Minerva Med 111(5):478–490. https://doi.org/10.23736/S0026-4806.20.07031-7
doi: 10.23736/S0026-4806.20.07031-7
pubmed: 32955830
Ga J, Arun I, Venzon D, Rj K, As W, Cm Y, Ge M, Stetler-Stevenson M (2011) Variables affecting the quantitation of Cd22 in neoplastic B cells. Cytometry B Clin Cytom 80(2):83–90. https://doi.org/10.1002/Cyto.B.20567
doi: 10.1002/Cyto.B.20567
Rosenthal J, As Naqvi, Luo M, Wertheim G, Paessler M, Thomas-Tikhonenko A, Rheingold SR, Pillai V (2018) Heterogeneity of surface Cd19 and Cd22 expression in B lymphoblastic leukemia. Am J Hematol 93(11):E352–E355. https://doi.org/10.1002/Ajh.25235
doi: 10.1002/Ajh.25235
pubmed: 30058145
European Medicines Agency “Besponsa” Assessement Report, Procedure No. Emea/H/C/004119/0000; https://www.Ema.Europa.Eu/En/Medicines/Human/Epar/Besponsa Accessed 08.04.2021
Fingrut W, Davis W, Dallas K, Ramadan K, Merkeley H, Leitch H, Mourad YA, Cassaday R, Ross C, Léger C (2019) Inotuzumab ozogamicin as salvage therapy for relapsed B-cell acute lymphoblastic leukemia with only very dim expression of Cd22 on circulating blasts. A case report. Clin Lymphoma Myeloma Leuk 19:S184. https://doi.org/10.1016/J.Clml.2019.07.021
doi: 10.1016/J.Clml.2019.07.021
Nn S, Ms S, Cm Y, Richards K, Delbrook C, Rj K, Pastan I, As W (2015) Characterization of Cd22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer 62(6):964–969. https://doi.org/10.1002/Pbc.25410
doi: 10.1002/Pbc.25410
Vyas M, Müller R, Pogge Von Strandmann E (2017) Antigen loss variants: catching hold of escaping foes. Front Immunol 8:175. https://doi.org/10.3389/Fimmu.2017.00175
doi: 10.3389/Fimmu.2017.00175
pubmed: 28286501
pmcid: 5323381
Stelmach P, Wethmar K, Groth C, Dv Wenge, Albring J, Mikesch J-H, Schliemann C, Reicherts C, We Berdel, Lenz G, Stelljes M (2020) Blinatumomab or inotuzumab ozogamicin as bridge to allogeneic stem cell transplantation for relapsed or refractory B-lineage acute lymphoblastic leukemia. A retrospective single-center analysis. Clin Lymphoma Myeloma Leuk 20(10):E724–E733. https://doi.org/10.1016/J.Clml.2020.05.022
doi: 10.1016/J.Clml.2020.05.022
pubmed: 32646833
Mr P, Wong V, Aristizabal P, Dj K (2019) Treatment of recurrent refractory pediatric pre-B acute lymphoblastic leukemia using inotuzumab ozogamicin monotherapy resulting in Cd22 antigen expression loss as a mechanism of therapy resistance. J Pediatr Hematol Oncol 41(8):E546–E549. https://doi.org/10.1097/Mph.0000000000001440
doi: 10.1097/Mph.0000000000001440
Gl R, Barraclough A, Cy F, Fleming S, Bajel A, Hofmann O, Westerman D, Grimmond S, Blombery P (2020) Inotuzumab ozogamicin resistance associated with a novel Cd22 truncating mutation in a case of B-acute lymphoblastic leukaemia. Br J Haematol 191(1):123–126. https://doi.org/10.1111/Bjh.16949
doi: 10.1111/Bjh.16949
Ej O, Han X, Tribouley C, Pa W, Rj L, Riester M, Je L, Qayed M, Sa G, Boyer M, De MB, Er N, Bittencourt H, Hiramatsu H, Buechner J, Sm D, Mr V, Nguyen K, Jl B, Bitter H, Morrissey M, Pierog P, Pantano S, Ja E, Winckler W (2018) Genetic mechanisms of target antigen loss in Car19 therapy of acute lymphoblastic leukemia. Nat Med 24(10):1504–1506. https://doi.org/10.1038/S41591-018-0146-Z
doi: 10.1038/S41591-018-0146-Z
Cherian S, Miller V, Mccullouch V, Dougherty K, Fromm JR, Wood BL (2018) A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-Cd19 therapy. Cytometry B Clin Cytom 94(1):112–120. https://doi.org/10.1002/Cyto.B.21482
doi: 10.1002/Cyto.B.21482
pubmed: 27598971
Burmeister T, Meyer C, Schwartz S, Hofmann J, Molkentin M, Kowarz E, Schneider B, Raff T, Reinhardt R, Gökbuget N, Hoelzer D, Thiel E, Marschalek R (2009) The Mll recombinome of adult Cd10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood 113(17):4011–4015. https://doi.org/10.1182/Blood-2008-10-183483
doi: 10.1182/Blood-2008-10-183483
pubmed: 19144982